APN sets FY 2027 targets: ZAR 9bn+ EBITDA and 50%+ NHEPS growth
Aspen Pharmacare says it delivered strong EBITDA and NHEPS growth despite flat revenue. It targets FY 2027 EBITDA over ZAR 9 billion, 50%+ NHEPS growth, and robust free cash flow, prioritizing share buybacks.
Achieved strong EBITDA and NHEPS growth despite flat revenue, driven by operational efficiencies, commercial pharma momentum, and recovery in steriles.
FY 2027 guidance targets over ZAR 9 billion EBITDA, 50%+ NHEPS growth, and robust free cash flow, with share buybacks prioritized.Based on Aspen Ph…